Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ribavirin dose and treatment outcome of Korean patients with genotype 1 chronic hepatitis C.

Hepato-gastroenterology - 1 Jan 2000

Sinn Dong Hyun, Kim Jeong, Shin Su Rin, Gwak Geum-Youn, Choi Moon Seok, Lee Joon Hyeok, Koh Kwang Cheol, Yoo Byung Chul, Paik Seung Woon

Abstract excerpt

BACKGROUND/AIMS: The current recommendation of ribavirin dose for the treatment of chronic hepatitis C is based on study results of Western patients, and might not be optimal for Korean patients because of different body frames. METHODOLOGY: A total of 163 treatment-naive genotype 1 chronic hepatitis C patients who received combination therapy with pegylated interferon a-2a and ribavirin were reviewed. RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Practice Guidelines as Topic

Share to Republic of Korea

Share to Ribavirin

Share to ROC Curve

Source

Identifiers

PMID: 21940368
DOI: 10.5754/hge11387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ribavirin dose and treatment outcome of Korean patients with genotype 1 chronic hepatitis C.PMID 21940368Read ↗

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Optimal therapy in genotype 1 patients.Semantic proximity Read ↗

Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era.Semantic proximity Read ↗

Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C.Semantic proximity Read ↗

Optimizing ribavirin dosage: a new challenge to improve treatment efficacy in genotype 1 hepatitis C patients.Semantic proximity Read ↗

A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.Semantic proximity Read ↗

Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.Semantic proximity Read ↗

[Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].Semantic proximity Read ↗

Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose.Semantic proximity Read ↗

[Virological response of chronic hepatitis C management with peg-interferon alpha-2b and ribavirin].Semantic proximity Read ↗

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.Semantic proximity Read ↗

Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.